Mpox: an updated review of dermatological manifestations in the current outbreak
British Journal of Dermatology,
Год журнала:
2023,
Номер
189(3), С. 260 - 270
Опубликована: Май 5, 2023
Abstract
Mpox
is
a
disease
caused
by
double-stranded
DNA
orthopoxvirus
discovered
in
1958.
In
2022,
an
outbreak
on
unprecedented
scale
marked
its
transition
from
neglected,
zoonotic
circulating
almost
exclusively
within
African
borders
to
sexually
transmitted
infection
(STI)
of
international
concern.
Although
phylogenetic
evidence
suggests
progressive
evolution
the
strain
associated
with
2018
Nigeria,
epidemiological
links
previous
cases
have
still
not
been
completely
elucidated.
Clinically,
mpox
presents
systemic
symptoms,
such
as
fever,
headache,
malaise
and
characteristic
cutaneous
eruption,
similar
that
cognate
viruses
(e.g.
smallpox).
pseudopustules
evolve
through
several
stages,
including
umbilication
crusting,
resolve
span
2–3
weeks.
The
hallmarks
set
2022
apart
classic
were
disproportionate
number
occurring
men
who
sex
men,
often
localized
picture
significant
burden
terms
concomitant
STIs.
Investigations
into
pathogenesis,
related
immune
response,
clinical
dermoscopic
features,
addition
studies
aimed
at
defining
novel
management
strategies,
advanced
knowledge
considerably.
Herein,
recent
findings
are
reviewed,
keen
focus
dermatological
manifestations
their
implications
current
diagnostic
scenario,
reinforcing
pivotal
role
dermatologists
managing
suspect
preventing
further
spread
contagion.
Язык: Английский
Preparedness, Prevention, Investigation, and Response to the Emergence of Mpox in Khartoum, Sudan in 2022
Опубликована: Июнь 4, 2024
Mpox,
formerly
known
as
Monkeypox,
is
a
rare
viral
disease
initially
discovered
in
Africa
1958.
Since
its
first
identification,
several
outbreaks
have
occurred
various
African
nations.
Recently,
the
global
community
has
witnessed
resurgence
number
of
Mpox
cases
reported
worldwide,
prompting
World
Health
Organization
(WHO)
to
declare
ongoing
multi-country
outbreak
public
health
emergency
July
2022.
This
study
reports
on
detected
Khartoum
State,
Sudan,
outlining
epidemiology,
preparedness,
and
response
this
new
challenge.
A
total
55
suspected
were
identified,
with
two
confirmed
cases.
The
clinical
manifestations
observed
these
align
classic
skin
rash
typical
presenting
alongside
symptoms
like
fever,
headache,
joint
pain.
findings
underscore
need
for
heightened
surveillance,
early
detection,
timely
intervention
prevent
domestic
spread
potential
impact
health.
Continued
efforts
are
needed
support
effective
screening,
diagnostic,
control
measures,
ultimately
enhancing
preparedness
face
emerging
disease.
Язык: Английский
Ocular manifestations of mpox
Current Opinion in Ophthalmology,
Год журнала:
2024,
Номер
35(5), С. 423 - 429
Опубликована: Июнь 6, 2024
To
highlight
the
clinical
features
of
mpox
with
an
emphasis
on
ocular
manifestations
and
to
review
treatment
options
for
this
re-emerging
infectious
disease.
Язык: Английский
Time-related change in mpox (monkeypox) skin lesions and their progression
Elsevier eBooks,
Год журнала:
2025,
Номер
unknown, С. 269 - 290
Опубликована: Янв. 1, 2025
Язык: Английский
Case Report: Mpox virus infection in a patient immunocompromised by human immunodeficiency virus with atypical evolution.
Infectio,
Год журнала:
2025,
Номер
unknown, С. 54 - 58
Опубликована: Фев. 22, 2025
Язык: Английский
Monkeypox: An Italian, multicentre study of 104 cases
Journal of the European Academy of Dermatology and Venereology,
Год журнала:
2023,
Номер
38(4)
Опубликована: Окт. 27, 2023
The
data
that
support
the
findings
of
this
study
are
available
from
corresponding
author
upon
reasonable
request.
Язык: Английский
Espectro de manejo farmacológico de la infección por viruela del mono durante el brote de 2022
Universitas Médica,
Год журнала:
2024,
Номер
64(4)
Опубликована: Янв. 31, 2024
Para
esta
revisión
de
la
literatura,
se
describieron
las
propuestas
planteadas
para
el
manejo
farmacológico
infección
por
viruela
del
mono
(Mpox)
durante
brote
2022.
Con
ese
objetivo,
realizó
una
búsqueda
sistematizada
literatura
utilizando
palabras
claves:
infections,
monkeypox,
therapeutics,
treatment
efficacy
en
Medline,
a
través
PubMed,
donde
identificaron
54
artículos
publicados
desde
2001
2023,
los
cuales
seleccionaron
26
ser
incluidos
resultados.
Se
encontró
que
tratamientos
más
documentados
tratar
Mpox
fueron
tecovirimat,
seguido
cidofovir
y
brincidofovir.
El
tecovirimat
fue
opción
terapéutica
segura
eficaz,
con
capacidad
reducir
carga
viral
tasa
supervivencia
al
menos
un
90
%.
Sin
embargo,
ninguno
tres
medicamentos
ha
aprobado
Administración
Alimentos
Medicamentos
Estados
Unidos
tratamiento
Mpox,
lo
reconoce
importancia
llevar
cabo
estudios
dirigidos
establecer
esquemas
mundial,
considerando
es
potencial
arma
biológica
todo
planeta.